Amiloride (MK-870): An Epithelial Sodium Channel Inhibitor Empowering Translational Ion Channel Research

Principle Overview: Mechanisms and Rationale for Amiloride (MK-870) in Research

Amiloride (MK-870), available through APExBIO's Amiloride (MK-870), is a highly regarded biochemical reagent recognized for its potency as an epithelial sodium channel inhibitor (ENaC) and urokinase-type plasminogen activator receptor inhibitor (uPAR). Its dual action enables precise modulation of sodium ion transport and receptor-mediated cellular processes, making it indispensable for researchers investigating ion channel blocking, cellular endocytosis modulation, and sodium channel research in health and disease contexts such as cystic fibrosis research and hypertension research.

Mechanistically, Amiloride (MK-870) blocks ENaC, reducing sodium reabsorption across epithelial tissues, and antagonizes uPAR, impacting downstream signaling pathways. This duality is particularly advantageous for dissecting the epithelial sodium channel signaling pathway and the urokinase receptor signaling pathway in both basic science and translational settings. The compound is supplied as a solid (molecular weight: 229.63; chemical formula: C6H8ClN7O) and should be stored at -20°C. Solutions are best prepared immediately before use, as long-term storage of solutions is not advised due to stability constraints.

Experimental Workflows: Step-by-Step Protocol Enhancements with Amiloride (MK-870)

1. Preparation and Handling

• Reconstitution: Dissolve Amiloride (MK-870) in DMSO or sterile water to the desired stock concentration (typically 10–50 mM). Vortex until homogenous.
• Aliquoting: Prepare single-use aliquots to avoid freeze-thaw cycles, minimizing degradation risk.
• Storage: Store powder at -20°C and use solutions promptly (<24 hours at 4°C), as per APExBIO’s recommendations.

2. Application in ENaC Functional Assays

• Cell Seeding: Plate epithelial cells (e.g., MDCK, H441, or primary airway cells) onto permeable supports for short-circuit current measurements or onto standard plates for fluorescence-based sodium uptake assays.
• Compound Treatment: Add Amiloride (MK-870) to the apical chamber at concentrations typically ranging from 1–100 μM. Optimization within this window is recommended based on cell type and endpoint.
• Readout: For electrophysiology, monitor changes in transepithelial voltage or current before and after inhibitor addition. For sodium uptake, utilize fluorescent sodium indicators or atomic absorption spectroscopy for quantification.

3. Investigating uPAR-Mediated Endocytosis

• Cell Preparation: Culture cell lines expressing uPAR (e.g., HEK293-uPAR, cancer cells).
• Labeling: Use uPA or uPAR ligands conjugated to fluorescent or radiolabels. Pre-treat cells with Amiloride (MK-870) (1–50 μM) for 15–30 min prior to ligand addition.
• Assay: Quantify ligand internalization by flow cytometry, confocal imaging, or radioactivity counting.

4. Disease Modeling: Cystic Fibrosis and Hypertension Research

• Cystic Fibrosis Models: Apply Amiloride (MK-870) to airway epithelial cultures or animal models to assess ENaC-dependent sodium hyperabsorption. Monitor airway surface liquid height, mucociliary clearance, and transepithelial sodium flux.
• Hypertension Models: In renal epithelial cell or organoid systems, evaluate the contribution of ENaC to sodium uptake under varying hormonal or pharmacological stimuli, with and without Amiloride (MK-870) treatment.

Advanced Applications and Comparative Advantages

Amiloride (MK-870) is uniquely positioned as a research-grade ion channel blocker with both ENaC and uPAR inhibitory activity. Its efficacy and selectivity, confirmed in recent benchmarks (see: advanced mechanistic review), enable nuanced interrogation of epithelial transport and receptor crosstalk.

• Cellular Endocytosis Modulation: The dual mechanism of Amiloride (MK-870) allows researchers to parse out ENaC-dependent and uPAR-mediated uptake, critical for studies of viral entry, metastatic signaling, and tissue remodeling (see: application in endocytosis studies).
• Comparative Selectivity: Compared to first-generation ENaC inhibitors or uPAR antagonists, Amiloride (MK-870) demonstrates superior target specificity with minimal off-target ion channel effects, as detailed in this advanced insights article. This is pivotal for translational models where confounding variables must be minimized.
• Quantitative Performance: In sodium uptake assays, Amiloride (MK-870) routinely achieves >85% inhibition of ENaC-mediated transport at 10 μM, with IC₅₀ values between 0.5–3 μM depending on cell type and assay format (see: performance benchmarking).

Troubleshooting and Optimization Tips

• Compound Solubility: Ensure complete dissolution in DMSO or water, and avoid excessive dilution into high-salt buffers that may precipitate the compound. If precipitation is observed, warm gently and vortex.
• Batch Variability: Always confirm the lot number and purity from APExBIO; minor impurities can impact ENaC or uPAR assay sensitivity.
• Concentration-Dependent Effects: While Amiloride (MK-870) is potent, effects above 100 μM may introduce off-target inhibition, especially in non-epithelial cell types. Titrate concentration for each model system.
• Assay Timing: Due to reversible inhibition, pre-incubate cells for at least 10 minutes before endpoint readout to ensure maximal target engagement. For chronic studies, re-dose as appropriate, given solution instability.
• Controls: Include vehicle (solvent) controls and, if possible, compare with alternate ENaC or uPAR inhibitors to validate specificity.
• Storage Stability: Discard any solution stored for more than 24 hours, as compound degradation can lead to inconsistent results.

Future Outlook: Expanding the Frontiers of Sodium Channel and Receptor Research

As the scientific community advances toward more personalized and mechanistically precise therapeutic strategies, tools like Amiloride (MK-870) are gaining renewed importance. The emergence of rare disease models, such as WHIM syndrome, highlights the need to dissect not only chemokine receptor function but also the broader network of ion channels and receptor-mediated endocytosis. The recent phase 3 trial of mavorixafor for WHIM syndrome elegantly demonstrates the translational power of targeted pathway inhibition—paralleling the experimental approaches enabled by Amiloride (MK-870) in preclinical settings.

Moreover, integration with high-throughput screening, CRISPR/Cas9-based engineering of epithelial and immune cells, and organoid platforms promises to further leverage Amiloride (MK-870) for dissecting complex cellular signaling pathways. The compound’s reliability, as provided by APExBIO, supports reproducibility and scalability in multi-site collaborations and large-scale phenotypic screens.

Interlinking the Knowledge Base

• Amiloride (MK-870): Epithelial Sodium Channel Inhibitor for Sodium Channel Research and Cellular Endocytosis Studies complements this article by providing a mechanistic dossier and recent benchmarks that reinforce Amiloride’s selectivity and application boundaries.
• Amiloride (MK-870): Epithelial Sodium Channel and uPAR Inhibitor extends the discussion to include systematic cataloging of biochemical rationale and research applications, valuable for designing comparative studies.
• Amiloride (MK-870): Advanced Insights into ENaC and uPAR Inhibition offers advanced perspectives on the translational impacts of ENaC/uPAR dual inhibition in disease modeling—an essential complement for researchers seeking to bridge bench and bedside.

Conclusion

Amiloride (MK-870) is an indispensable tool for advancing sodium channel research, receptor-mediated signaling studies, and disease modeling in cystic fibrosis and hypertension. Its dual action as an epithelial sodium channel inhibitor and urokinase-type plasminogen activator receptor inhibitor provides unmatched specificity and functional flexibility. Backed by APExBIO’s stringent quality controls, it delivers reproducible results across diverse experimental platforms. As the field moves toward more integrative and translational approaches, the scientific community can rely on Amiloride (MK-870) to illuminate the complexities of epithelial transport and receptor signaling pathways in both common and rare disease contexts.